Introduction
Saponins, a group of amphiphilic glycosides containing sugar chains, are responsible for the pharmacological activities of many herbal medicines and dietary supplements (Vincken et al., 2007) . For example, Timosaponin B-II (TB-2), also known as (25S) Anemarrhena asphodeloides . TB-2 has multiple reported pharmacological activities, such as protecting against high glucose-induced apoptosis (Guo et al., 2014b) and inhibiting superoxide generation in human neutrophils , as well as antiplatelet, antithrombotic (Lu et al., 2011) , and anti-inflammatory (Lu et al., 2009) activities. Interestingly, TB-2 also promotes learning and memorization in memory-deficit rat models (Li et al., 2007) , making it a potential candidate for anti-dementia treatment.
Despite wide interest in the pharmacological effects and mechanisms of TB-2, its pharmacokinetic behavior and the mechanism of its disposition have not been fully explored. The reported absolute bioavailability of TB-2 in rats is only 1.1 ± 0.3%, with a double peak in the plasma concentration (Cai et al., 2008) . The biliary excretion of TB-2 after intravenous injection was found to be comparable to urinary excretion but was greater than fecal excretion (Xu et al., D M D # 5 9 9 2 3 5 injection (Zhang et al., 2013) . Glycyrrhizin, a triterpene saponin with low bioavailability (4%), is a substrate of multidrug resistance-associated protein 2 (Mrp2), which mediates biliary excretion (Makino et al., 2008) , consistent with 98% of unmodified glycyrrhizin being excreted into the bile after intravenous administration (Yamamura et al., 1991) . However, to the best of our knowledge, there is no published study to clarify the contribution of hepatic transporters to the hepatobiliary disposition of TB-2, and the metabolic capacity of TB-2 in the liver has not been characterized.
In this study, the metabolic and liver disposition of TB-2 was thoroughly investigated from multiple perspectives using in vitro tools. The concentration of TB-2 in rat plasma, liver and bile after oral administration was also assessed. Furthermore, the drug-drug interaction (DDI) between rosuvastatin and TB-2 was examined to verify the role of transporters in the hepatobiliary disposition of TB-2. Metabolism of TB-2 in rat S9 fractions, microsomes, and primary hepatocytes. The metabolic profile of TB-2 was investigated using rat S9 fractions, microsomes, and freshly isolated primary rat hepatocytes. Hepatocytes were isolated from male SD rats by a previously described two-step perfusion (Shen et al., 2012) . The hepatocytes were incubated in six-well plates at a density of 0.5 × 10 6 /per well, followed by the immediate addition of 1 μ M TB-2. The cells were incubated in an orbital shaker at 37 °C for 3 h. Cell suspensions (300 µl) were collected at 0 and 3 h, and ice-cold methanol (300 µl) was added immediately to terminate potential reactions. The cell samples were then lysed by sonication, and 200 µl samples were extracted by liquid-liquid extraction. To observe TB-2 (1 μ M) metabolism in S9 fractions and microsomes, we adjusted the protein density of the rat hepatic S9 fractions and microsomal enzymes systems to 1 mg/ml with 100 mM of phosphate buffer before sample incubation. Bovine serum albumin was used as a control treatment. The samples were supplemented with 1 mM NADPH and 4 mM glutathione, as previously reported (Wolf et al., 1986) . Testosterone (5 µM) was used as a positive control. The systems were then incubated in a water bath (37 °C) for 3 h. Samples (300 µl) were collected at 0 and 3 h, and ice-cold methanol (300 µl) was added immediately to terminate potential reactions.
Accumulation of TB-2 in primary hepatocytes. The following two protocols were performed to evaluate the hepatocellular accumulation of TB-2.
Protocol 1. The accumulation study was conducted according to a previously described method, with slight modifications (Swift and Brouwer, 2010; Marion et al., 2011; Guo et al., 2014a Protocol 2. Temperature-dependent accumulation was determined by incubating the hepatocytes with warm (37 °C) and cold (4 °C) dosing solution, as previously described (Sharma et al., 2013) . In brief, hepatocytes were incubated in warm (37 °C) and cold (4 °C) media with 1 ml of dosing solution (HBSS containing 10 μ M TB-2). The remainder of the protocol was the same as described for protocol 1. 
Accumulation of TB-
where V max is the maximum uptake rate (pmol/min per mg of protein), K m is the Michaelis constant (μM) and S is the substrate concentration (pmol/mg of protein).
The contribution of OATP1B1 and OATP1B3 to compound uptake in hepatocytes was evaluated according to previously described methods (Kitamura et al., 2008) . In brief, the relative active factor (R value) was the reported ratio of the uptake of rosuvastatin in human hepatocytes (CL hepatocyte ) to that in transporter-expressing cells (CL transporter ) (Kitamura et al., 2008) . The calculation was as follows: (Kitamura et al., 2008) were used to evaluate the contribution of OATP1B1 and OATP1B3 to TB-2 uptake. A OATP is the amount accumulated in transporter-expressing cells, and T is the time for accumulation in transfected cells.
Biliary excretion of TB-2 in sandwich-cultured rat hepatocytes (SCRHs). SCRHs were established according to previously described methods with minor modifications (Chandra et al., 2005) . In brief, after primary rat hepatocytes were isolated and plated in 24-well plates, the cells were washed and cultured with William's E medium containing fetal bovine serum (5%). After two days, 0.25 mg/ml BD Matrigel dissolved in ice-cold William's E medium without fetal bovine serum was overlaid on the plates. The culture medium was changed daily, and the experiment was performed on day 5 of culture (day 1 was the time of plating). In brief, SCRHs were pre-incubated in 300 µl of warm HBSS with or without Ca 2+ at 37 °C for 15 min; the tight junctions of the bile canaliculi open temporally following exposure to HBSS without Ca 2+ . At the end of pre-incubation, the buffer was aspirated, and the hepatocytes were incubated with 300 µl of dosing solution (HBSS with Ca 2+ ) to initiate uptake (15 min, 37 °C). The tested compounds included TB-2 (5 μ M) with or without the inhibitors Ko143 (100, 250, 500 µM) or MK-571 (10, 100 µM).
The dosing solution was aspirated from the plates after incubation, and uptake was terminated by washing the cells twice with ice-cold phosphate buffer. After the remaining buffer was aspirated, the cell samples were lysed by sonication in 1 ml of water after three freeze-thaw cycles, and approximately 20 µl of the cell sample was used to determine the protein concentration. The
This article has not been copyedited and formatted. The final version may differ from this version. (Liu et al., 1999; Pan et al., 2012) :
Transport study of TB-2 with human BCRP-and MRP2-expressing membrane vesicles.
Inside-out membrane vesicles were purchased from Genomembrane (Kanazawa, Japan). The vesicular transport study was performed using a rapid filtration technique according to the Pharmacokinetics of TB-2 in rats. Rats were randomly assigned to two groups and fasted overnight with free access to water before dosing. All rats were administered an oral dose of TB-2 (30 mg/kg, dissolved in saline). At 0.167 h, 0.5 h, 1 h, 2 h, and 6 h, 25 rats in group A (n =5 for each time point) were anesthetized with urethane (1.4 g/kg, dissolved in saline) and sacrificed to collect hepatic portal venous plasma, abdominal aorta plasma and the liver. Five rats in group B
were cannulated with PE-10 polyethylene tubing under anesthesia, and bile was collected at 0-2 h, This article has not been copyedited and formatted. The final version may differ from this version. 2-4 h, 4-6 h, 6-8 h, 8-10 h, and 10-24 h after dosing. The blood and bile samples were centrifuged at 10000 rpm for 5 min, and all samples were stored at -20 °C until analysis.
The fraction (f bile ) of biliary clearance (CL bile ) of the total clearance (CL total ) was calculated as follows:
s the oral dose of TB-2; AUC oral is the area under time-concentration in plasma after oral administration; M bile is the amount of TB-2 excreted into bile; and F is the bioavailability of TB-2, for which the reported value of 1.1% was used (Cai et al., 2008) .
DDI between TB-2 and rosuvastatin in hepatocytes and SCRHs. The accumulation study
of DDI between TB-2 and rosuvastatin was as same as protocol 1 of the uptake study on TB-2, except that the victim compound used was rosuvastatin and TB-2 was employed as the perpetrator.
The impact of TB-2 on rosuvastatin biliary excretion was also assessed in SCRHs.
DDI between TB-2 and rosuvastatin in rats. Rats were assigned to six groups (n = 4 for each group). Rosuvastatin (5 mg/kg, dissolved in saline) was administered to the rats in group C by oral gavage. Rosuvastatin (5 mg/kg, dissolved in saline) and TB-2 (30, 60, and 180 mg/kg, dissolved in saline) were co-administered to the rats by oral gavage in groups D, E, and F,
respectively. Approximately 300 µl of blood sample was collected from the orbital vein at 0.08, 0.25, 0.5,1, 2, 3, 4, 6, 8, and 10 h under light ether anesthesia. Food was withheld during this process, but water was freely provided. Plasma samples were obtained after centrifugation at
For the biliary excretion analysis, rosuvastatin (1 mg/kg, dissolved in saline) was injected 0.5 h in advance into the rat tail vein after oral administration with TB-2 (180 mg/kg, in group G) or saline (in group H). The fasted rats were anesthetized by intraperitoneal injection of urethane. A polyethylene tube (PE-10) was inserted into the common bile duct for bile collection, and bile samples were collected at 0-0.25 h, 0.25-0.5 h, 0.5-1 h, 1-1.5 h, 1.5-2 h, and 2-3 h after oral administration. All the samples were stored at -20 °C until analysis.
Quantification by LC-MS/MS. All samples were analyzed using a Shimadzu LCMS-8030 triple quadrupole system (Shimadzu Corp., Japan) equipped with electrospray ionization (ESI).
Data processing was performed using Shimadzu LC-MS Lab Solution System version 5.42 SP4
(Shimadzu Corp., Japan). Chromatographic separation was performed on an ACE C18 column and the flow rate was 0.2 ml/min. The gradient parameters for TB-2 were 88% B to 70% B at 0 min to 0.1 min, 70% B at 0.1 min to 2.0 min, 70% B to 10% B at 2.0 min to 2.5 min, 10% B at 2.5 min to 3.0 min, 10% B to 88% B at 3.0 min to 3.5 min, and 88% B at 3.5 min to 7.5 min. The gradient parameters for rosuvastatin were 62% B at 0 min to 2.0 min, 62% B to 25% B at 2.0 min to 3.5 min, and 62% B at 3.51 min to 7.5 min. All test compounds showed good linearity, with an This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Metabolism of TB-2 in rat S9 fractions, microsomes, and primary hepatocytes. The metabolism of the reference compound testosterone was higher than 90% in rat S9 fractions (Figure 2A ), microsomes ( Figure 2B ), and primary hepatocytes ( Figure 2C ). However, no significant difference in the concentration of TB-2 was observed in the presence or absence of S9 fractions, microsomes or hepatocytes ( Figure 2D -2E ), indicating that metabolism is not the major clearance pathway for TB-2 in the liver. Moreover, no metabolites were detected in the TB-2-containing samples after a full scan by HPLC-Q-TOF (Agilent Corp, USA) (data not shown).
Accumulation of TB-2 in primary rat hepatocytes. To determine the contributions of passive diffusion and active uptake to TB-2 hepatic transport, the effect of temperature was evaluated in primary hepatocytes. As shown in Figure 3A , the concentration of TB-2 in hepatocytes was reduced to approximately 6.7% in cold (4 °C) medium compared to warm (37 °C) medium (2.96 ± 0.31 vs. 44.18 ± 1.75 ng/mg protein), indicating that the transport of TB-2 in primary hepatocytes is mainly dependent on active transport. Furthermore, the Oatp inhibitors rifampicin (P < 0.001), probenecid (P < 0.01), and BSP (P < 0.01) significantly reduced the uptake of TB-2 (20 μ M) by rat primary hepatocytes ( Figure 3B ). The most prominent inhibition was induced by rifampicin: TB-2 uptake was reduced up to 90.7% by rifampicin in a dose-dependent manner ( Figure 3C ).
Accumulation of TB-2 in OATP1B1-and OATP1B3-transfected HEK293 systems.
Because Oatp inhibitors inhibited TB-2 accumulation in hepatocytes, we suspected that TB-2 was a substrate for Oatp. To test this hypothesis, TB-2 uptake in OATP1B1-and OATP1B3-HEK293 systems was investigated. As depicted in Figure 4A , rosuvastatin accumulation increased This article has not been copyedited and formatted. The final version may differ from this version. 
Biliary excretion of TB-2 in SCRHs and BCRP-and MRP2-expressing membrane
vesicles. Figure 6 shows that after a 15-min incubation in SCRHs, the BEI of TB-2 ranged from 43.1% to 44.9%, indicating that biliary excretion plays an important role in TB-2 hepatobiliary disposition. The Bcrp inhibitor Ko143 and Mrp2 inhibitor MK-571 (Yamazaki et al., 2005; Weiss et al., 2007) significantly decreased the TB-2 BEI values from 44.9% to 12.7% ( Figure 6A ) and 43.1% to 15.2% ( Figure 6B ), respectively. In addition, the concentrations of TB-2 were significantly higher in both BCRP-and MRP2-expressing membrane vesicles than in Mock-expressing membrane vesicles (the control group) (P < 0.05) ( Figure 6C ).
Pharmacokinetic study of TB-2 in rats.
As shown in Figure 7A , the concentration of TB-2 was approximately 1.5-fold higher in portal vein plasma than in abdominal aorta plasma, in agreement with the corresponding AUC values (55.2 ± 18.2 vs. 24.6 ± 6.6 h*ng/ml). Significant double peaks were observed in both plasma and liver samples ( Figure 7A and 7B).
After oral administration of a 30 mg/kg dose of TB-2, the highest concentration in bile was This article has not been copyedited and formatted. The final version may differ from this version. 11.2 ± 4.1 µg/ml at 2-6 h, and the accumulated biliary excretion of TB-2 was as high as 59.7 ± 11.8 µg ( Figure 8A and 8B). Considering that the bioavailability of TB-2 is 1.1% (Cai et al., 2008) , this biliary clearance value represents 70% of the absorbed oral dose (eqs. 6-8) DDI between TB-2 and rosuvastatin in hepatocytes. The accumulation of rosuvastatin (5 µM) was reduced in a concentration-dependent manner by TB-2 (IC 50 = 5.27 µM) in hepatocytes after a 15-min incubation ( Figure 9A ). Moreover, rosuvastatin accumulation in hepatocytes was a concentration-dependent process that was partly inhibited by TB-2 (20 µM) in a concentration range of 1-15 µM ( Figure 9B ). Although the V max of rosuvastatin uptake in hepatocytes was not significantly influenced by TB-2 (11.0 vs. 10.8 pmol/min/mg of protein), the K m did increase from 2.8 μ M to 7.8 μ M (Table 1) .
TB-2 decreased the BEI of rosuvastatin in SCRHs as well. In particular, the BEI of rosuvastatin was reduced from 42.8% to 18.7% as the TB-2 concentration increased from 0 to 20 µM ( Figure 10 ).
DDI between TB-2 and rosuvastatin in rats.
The plasma concentration of rosuvastatin increased significantly when co-administered with TB-2. After co-administration with TB-2 at doses of 30-180 mg/kg, C max increased from 46.1 ± 13.9 to 97.0 ± 22.8 ng/ml, and the AUC of rosuvastatin increased in a dose-dependent manner from 113.0 ± 7.8 to 282.2 ± 74.4 h* ng/ml ( Figure 11 , Table 2 ).
The rosuvastatin concentration in bile decreased ( Figure 12A ) and the total biliary excretion decreased by 50% (1566.8 
Discussion
In this study, the hepatobiliary disposition and metabolism of TB-2 were explored to characterize the absorption, distribution, metabolism, and excretion (ADME) profile and identify potential DDIs of this promising drug candidate.
Because no metabolism was observed in the rat S9 fractions, the microsomes, or the primary hepatocytes (Figure 2 ), TB-2 metabolism may not play an important role in its elimination.
Because TB-2 uptake by hepatocytes was highly temperature dependent (active uptake accounted for 93% of TB-2 accumulation) ( Figure 3A) , the connection between TB-2 and liver uptake transporters was further investigated. The accumulation of TB-2 in rat primary hepatocytes was significantly inhibited by multiple Oatp inhibitors, including rifampicin, probenecid and BSP ( Figure 3B ). For example, 20 μ M rifampicin reduced TB-2 accumulation in primary hepatocytes by 90.7% ( Figure 3C ), indicating that its accumulation is highly dependent on Oatp transporters.
In particular, OATP1B1 and OATP1B3 are expressed in the human liver and play significant roles in the uptake of substrates into hepatocytes (Kindla et al., 2009 ). Additionally, a comparison of TB-2 accumulation in OATP1B1-and OATP1B3-transfected HEK293 cells revealed that OATP1B1 and OATP1B3 could significantly increase TB-2 uptake into these cells (Figure 4) .
Calculations of the effects of these polypeptides on TB-2 (eqs. 2-4) revealed that the contribution of OATP1B1 to TB-2 uptake reached 92%-98%, suggesting that it plays a dominant role in this process in hepatocytes. The cellular kinetic parameters of OATP1B1 were also determined (K m = 3.69 ± 0.46 µM, V max = 12.94 ± 0.40 pmol/min/mg of protein) ( Figure 5 ). Considering that Oatp1b2 in rats has an expression profile similar to that of human OATP1B1/1B3 (Hagenbuch and Meier, 2003) , Oatp1b2 is expected to be the uptake transporter for TB-2 in the rat liver.
This article has not been copyedited and formatted. The final version may differ from this version. Bcrp and Mrp2 are expressed in rat hepatocytes on the canalicular membrane side and are responsible for the biliary excretion of various substrates. The BEI of TB-2 in SCRHs was significantly reduced by Ko143 (a Bcrp inhibitor) and MK-571 (an Mrp2 inhibitor), suggesting that TB-2 is a substrate of Bcrp and Mrp2. The concentration of TB-2 in human BCRP-or MRP2-expressing membrane vesicles was significantly higher than that in Mock-expressing membrane vesicles (Figure 6 ), further verifying that TB-2 is a substrate of human BCRP and MRP2. Because the substrate and inhibitor specificities of human and rat BCRP/MRP2 are similar (Grime and Paine, 2013) , TB-2 may also a substrate of Bcrp/Mrp2 in rats.
Obvious double peaks in rat plasma were previously observed after oral administration of TB-2 (Cai et al., 2008) or herbal medicine (Cai et al., 2010) . In this study, distinct double peaks were observed not only in portal vein plasma and abdominal aorta plasma but also in the liver after oral administration (Figure 7 ). TB-2 was excreted into the bile, and the highest concentration in the bile was of 11.2 ± 4.1 µg/ml. Moreover, biliary excretion accounted for up to 70% of the absorbed oral dose (Figure 8 ), consistent with its high BEI values (43.1% to 44.9%). Another group has reported that the distribution of TB-2 in the small intestine achieves a maximum concentration at 60 min after intravenous dosage compared to 10 min for other organs, providing further evidence of active TB-2 biliary excretion (Xu et al., 2014 ) that can be attributed to the cooperation of the hepatic uptake (Oatp) and efflux transporters (Bcrp/Mrp2). In fact, in transwell studies, the permeation of Bcrp-or Mrp2-transfected MDCK cell monolayers by TB-2 was limited in the absence of an auxiliary uptake transporter (data not shown). Therefore, we speculate that TB-2 hepatobiliary disposition occurs as follows: TB-2 is absorbed into the portal vein and then in the rat plasma (10 min) and liver (30 min). A small fraction of TB-2 accumulates in the liver in the absence of metabolism, but it is mainly excreted into bile (f bile = 70%) via efflux transporters (Bcrp/Mrp2), thus leading to enterohepatic circulation and contributing to the second peaks in the liver (2 h) and plasma (1 h). Indeed, biliary excretion may not be the only reason for its second absorption peak. Different TB-2 absorption sites in the gut may also have contributed to the second plasma peak, and the remaining TB-2 in the gut and the biliary-excreted TB-2 could have been absorbed together. Otherwise, it is difficult to explain why the second peak was as high as the first one ( Figure 7 ). Further investigation is needed to verify this hypothesis. Although evidence suggests that Oatp or Mrp2 alone may contribute to liver accumulation or biliary excretion of saponins such as dioscin and glycyrrhizin (Makino et al., 2008; Zhang et al., 2013) , this is the first report of cooperation by uptake transporters (Oatp) and efflux transporters (Bcrp/Mrp2) in the hepatobiliary disposition of saponins.
Although 70% of the absorbed TB-2 was excreted into the bile and a significant double-peak phenomenon was observed, the bioavailability of TB-2 was only 1.1% after oral administration of 180 mg/kg (Cai et al., 2008) . Another group has reported that the bioavailabilities of TB-2 were 0.62% and 0.55% after oral administration of 30 and 180 mg/kg, respectively, implying the linearity of TB-2 pharmacokinetics within the tested dose range (Xu, 2013) . Considering that passive diffusion accounts for only approximately 7% of TB-2 uptake across the hepatic membrane ( Figure 3A ) and that TB-2 is a substrate of Bcrp and Mrp2, its low permeability in the gut is not surprising. This low passive permeability may prevent its absorption, and efflux transporters (Bcrp/Mrp2) may pump it back into the intestinal tract. The low passive permeability of TB-2 may result from its unfavorable physicochemical traits, including its large molecular mass This article has not been copyedited and formatted. The final version may differ from this version. (921, favorable value < 500 Da), high hydrogen-bonding capacity (31, favorable value < 12) and high molecular flexibility (25, favorable value < 10), which lead to poor membrane permeability and hinder intestinal absorption (Yu et al., 2012) . Moreover, metabolism in the gastrointestinal tract may also impede TB-2 absorption, as the deglycosylation of many saponins occurs in the gastrointestinal tract via the action of colonic microflora (Hasegawa et al., 1996) . Indeed, because deglycosylated metabolites of TB-2 have been detected in the gastrointestinal contents and urine of rats Xu, 2013) , gastrointestinal metabolism should be further explored to clarify its contribution to the poor bioavailability of TB-2.
Rosuvastatin is a substrate of Oatp, Bcrp, and Mrp2, and its metabolism is limited (Nezasa et al., 2002; Kitamura et al., 2008) , which highly overlaps with the ADME spectrum of TB-2. Thus, rosuvastatin was chosen as a probe to investigate the potential DDI between rosuvastatin (victim) and TB-2 (perpetrator). TB-2 reduced the accumulation of rosuvastatin in primary hepatocytes (IC 50 = 5.27 µM) ( Figure 9A ) and the BEI of rosuvastatin in SCRHs (42.8% vs. 18.7%) ( Figure   10 ). Moreover, the significant change in the K m of rosuvastatin (2.8 μ M vs. 7.8 μ M) without a significant change in its V max implies a competitive process (Table 1) . These results are consistent with the in vivo observations that TB-2 increased the AUC of rosuvastatin from 113.0 ± 7.8 to 282.2 ± 74.4 h*ng/ml dose dependently ( Figure 11 , Table 2 ) and decreased its biliary excretion by approximately 50% ( Figure 12B ). These data confirm the previous hypothesis that TB-2 and rosuvastatin share similar influx and efflux transporters. The transporter spectrum of some saponins may overlap with those of statins. For example, ginsenoside Rh 2 isolated from ginsenoside is a substrate of BCRP (Jin et al., 2006) , and glycyrrhetic acid derived from licorice is a moderate inhibitor of MRP2 and BCRP (Yoshida et al., 2008) . Although this overlap may lead to This article has not been copyedited and formatted. The final version may differ from this version. The involvement of multiple transporters complicates TB-2-related pharmacokinetic and toxicity processes due to the potential for interindividual variability. For example, some single-nucleotide polymorphisms (SNPs) of the genes encoding OATP, BCRP and MRP2 have been associated with alterations in the PK profiles of statins (Niemi et al., 2006; Xiang et al., 2006; Hua et al., 2012; Konig et al., 2013) . The increased expression of OATP and decreased expression of MRP2 may also alter pharmacokinetic parameters and disposition in patients with diabetes (Jung et al., 2001; Kast et al., 2002; Hasegawa et al., 2010) . Because TB-2 is a substrate of both OATP and MRP2 and has potential value for preventing diabetic cardiovascular complications (Guo et al., 2014b) , it should be used judiciously in diabetes patients, particularly when co-administered with a statin.
In summary, our study demonstrates that influx (Oatp) and efflux transporters (Bcrp/Mrp2), but not metabolic enzymes, contribute significantly to rat TB-2 hepatobiliary disposition.
Moreover, TB-2 interferes with the rosuvastatin PK profile and biliary excretion, as they share similar transporters. Additional work is needed to clarify the reasons for the poor bioavailability of TB-2, and a schematic representation of this process is presented in Supplemental Figure 1 .
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